Bloomberg Intelligence: Nvidia to Invest in MediaTek (Podcast)

This is less about headline M&A and more about control points. NVIDIA is effectively buying deeper penetration into the server stack, which should widen switching costs around its interconnect standards and make it harder for hyperscalers to architect around the platform over the next 6-18 months. The near-term read-through is strongest for NVDA; the second-order losers are alternative accelerator and custom-silicon ecosystems that depend on open interconnects, especially if this becomes a template for broader OEM adoption.

For Lilly, the strategic value is duration, not this year’s EPS. Management is using obesity-generated cash flow to buy optionality in autoimmune/allergy, which can support a premium multiple if it keeps compounding outside the obesity franchise. The market may underappreciate that the real bull case is not one asset but a repeatable capital-allocation engine that extends Lilly’s growth runway beyond the current consensus window.

AON’s transaction matters most as a competitive signal: scale is being rewarded in middle-market brokerage, and that can slowly pressure smaller intermediaries on pricing and retention. KKR’s realized gain is a clean positive for private-markets sentiment, but it is a one-off unless exit markets stay open; the better read-through is to BX/APO/CG on whether monetization is improving broadly. The Anthropic IPO angle is a liquidity event risk for late-stage private tech, but it is more a 1-3 month capital-allocation headwind than a fundamental threat to public AI leaders.